Obama administration officials and Mylan N.V. are declining to send representatives to testify at a Senate Judiciary Committee hearing this month that would explore the government’s $465 million settlement with the pharmaceutical company over its alleged misclassification of the life-saving device EpiPen for purposes of Medicaid rebates.
Sen. Chuck Grassley, R-Iowa, chairman of Senate Judiciary, has questioned the fairness of the deal that Mylan said it had reached in October with the U.S. Justice Department and regulatory agencies. The settlement, which Mylan announced in a news release, came amid the public outcry over Mylan’s decision to increase the price of its epinephrine auto-injector EpiPen.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
